President Trump signed an executive order reducing the number of universally recommended childhood vaccines to 11 and calling for the separation of the MMR vaccine. This move could impact pharmaceutical companies producing combination vaccines and introduces uncertainty into public health policy regarding vaccinations.
President Trump's executive order significantly alters federal childhood vaccine recommendations, narrowing the 'gold standard' list to 11 and pushing for the separation of the combined MMR vaccine. This is a macro policy shift that directly impacts pharmaceutical companies like Merck, GSK, and Sanofi, which produce these combination vaccines. In the short term, these companies may face pressure to develop single-dose alternatives, potentially incurring R&D costs and market disruption. Long-term implications include a potential shift in vaccine purchasing patterns and public health policy, which could affect vaccine uptake rates. The order also reignites controversial claims linking vaccines to autism, which could lead to increased vaccine hesitancy and political debate, posing a risk to public health and the vaccine market.